化疗联合经典名方小柴胡汤治疗乳腺癌疗效及安全性的Meta分析OA

Objective:To systematically evaluate the efficacy and safety of chemotherapy combined with the classic prescription Xiaochaihu(小柴胡)Decoction in the treatment of breast cancer by meta-analysis and provide evidence-based medical evidence support.Methods:Randomized controlled studies on chemotherapy combined with Xiaochaihu Decoction for treating breast cancer that were published before January 1,2026 were searched against PubMed,Embase,The Cochrane Library,Web of Science,CNKI,Wanfang Data,VIP,and SinoMed.RevMan5.3 was used for data analysis.Results:Seventeen studies were included,with 1 292 patients.The results of meta-analysis showed that compared with chemotherapy alone,chemotherapy combined with Xiaochaihu Decoction improved the clinical response rate[RR=1.45,95%CI(1.30,1.62),P<0.01],decreased the levels of carbohydrate antigen 125(CA125)[MD=-41.26,95%CI(-53.32,-29.20),P<0.01],carbohydrate antigen 153(CA153)[MD=-15.28,95%CI(-16.81,-13.75),P<0.01],carcinoembryonic antigen(CEA)[MD=-3.73,95%CI(-4.23,-3.24),P<0.01],insulin-like growth factor-1(IGF-1)[MD=-58.09,95%CI(-59.97,-56.21),P<0.01],and soluble E-cadherin(sEC)[MD=-0.79,95%CI(-0.82,-0.77),P<0.01],increased T lymphocytes(CD3+,CD4+,and CD4+/CD8+)[MD=0.31,95%CI(0.25,0.36),P<0.01],inhibited CD8+expression[MD=-5.88,95%CI(-6.52,-5.24),P<0.01],raised the levels of immunoglobulins A,M,and G[MD=0.50,95%CI(0.47,0.53),P<0.01],lowered the levels of tumor vascular endothelial growth factors A[MD=-6.98,95%CI(-8.68,-5.28),P<0.01]and B[MD=-5.82,95%CI(-7.73,-3.90),P<0.01],and alleviated adverse reactions after chemotherapy.Conclusion:Chemotherapy combined with Xiaochaihu Decoction in the treatment of breast cancer can improve the clinical response rate,elevate the levels of T lymphocytes and immunoglobulins,inhibit CD8+expression,lower the levels of tumor markers and tumor vascular endothelial growth factors,and reduce adverse re-actions.The conclusion remains to be validated by more high-quality,multi-center,and large-sample studies.